Home >> MARKETPLACE >> National Jewish Health launches assay for NTM drug resistance

National Jewish Health launches assay for NTM drug resistance

Print Friendly, PDF & Email

February 2019—National Jewish Health Advanced Diagnostic Laboratories has launched a line probe assay to detect nontuberculous mycobacteria infections and identify NTM species and drug-resistance markers at a molecular level within 48 hours after obtaining a sample from culture.

The NTM-DR line probe assay allows rapid differentiation of M. tuberculosis from several frequently encountered NTM species, including the slowly growing M. avium, M. intracellulare, and M. chimaera species as well as several rapidly growing mycobacteria, including M. abscessus and its subspecies. The assay also identifies genetic markers associated with macrolide and aminoglycoside resistance, two drugs used for the treatment of NTM infections.

National Jewish Health Advanced Diagnostic Laboratories, 303-398-1339

X